PE20180044A1 - Compuestos novedosos - Google Patents
Compuestos novedososInfo
- Publication number
- PE20180044A1 PE20180044A1 PE2017002302A PE2017002302A PE20180044A1 PE 20180044 A1 PE20180044 A1 PE 20180044A1 PE 2017002302 A PE2017002302 A PE 2017002302A PE 2017002302 A PE2017002302 A PE 2017002302A PE 20180044 A1 PE20180044 A1 PE 20180044A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- group
- compounds
- rip2 kinase
- arylalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se refiere a un compuesto de Formula I, en la que X representa N o CH, R1 es H, -SO2 alquilo (C1-C4), o alquilo (C1-C4); R2 es SRa, -SORa, entre otros, en donde Ra es alquilo (C1-C6), halo alquilo (C1-C6) heterocicloalquilo, arilo o hereroarilo de 4-7 miembros, en donde dicho alquilo (C1-C6) esta sustituido opcionalmente por uno o dos grupos cada uno seleccionado independientemente del grupo que consiste en ciano, hidroxilo alcoxi, entre otros. Z es fenilo o arilalquil (C1-C4)-, en el que el grupo fenilo o el resto arilo del grupo arilalquil (C1-C4)- esta sustituido con R4, R5, R6, R7; R4 es H, halogeno, ciano, entre otros; Cada uno de R5, R6 y R7 esta seleccionado independientemente del grupo que consiste en H, hidroxilo, halogeno, entre otros. L es un grupo de enlace que comprende una longitud de 4-16 atomos en su longitud mas corta. Dichos compuestos modulan la actividad de la cinasa RIP2 incluyendo la degradacion de la misma que comprenden inhibidores de cinasa RIP2. Tambien se refiere a refiere a compuestos, composiciones, combinaciones y medicamentos que contienen dichos compuestos y a procedimientos para su preparacion. En donde pueden ser utiles para el tratamiento de enfermedades alergicas, autoinmunitarias; o estados inflamatorios, o cualquier estado mediado por la cinasa RIP2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506872.9A GB201506872D0 (en) | 2015-04-22 | 2015-04-22 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20180044A1 true PE20180044A1 (es) | 2018-01-15 |
Family
ID=53299021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017002302A PE20180044A1 (es) | 2015-04-22 | 2016-04-20 | Compuestos novedosos |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10435391B2 (es) |
| EP (1) | EP3286169B1 (es) |
| JP (1) | JP2018513867A (es) |
| KR (1) | KR20170139096A (es) |
| CN (1) | CN107709305B (es) |
| AU (1) | AU2016252404B2 (es) |
| BR (1) | BR112017022604A2 (es) |
| CA (1) | CA2983414A1 (es) |
| CL (1) | CL2017002650A1 (es) |
| CO (1) | CO2017011851A2 (es) |
| CR (1) | CR20170478A (es) |
| EA (1) | EA033343B1 (es) |
| ES (1) | ES2841548T3 (es) |
| GB (1) | GB201506872D0 (es) |
| HK (1) | HK1243410A1 (es) |
| IL (1) | IL255067A0 (es) |
| MX (1) | MX375674B (es) |
| PE (1) | PE20180044A1 (es) |
| PH (1) | PH12017501921A1 (es) |
| SG (1) | SG11201708311UA (es) |
| WO (1) | WO2016172134A2 (es) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US10071164B2 (en) * | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2016118666A1 (en) | 2015-01-20 | 2016-07-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of the androgen receptor |
| JP7269731B2 (ja) | 2015-03-18 | 2023-05-09 | アルビナス・オペレーションズ・インコーポレイテッド | 標的タンパク質の分解向上のための化合物および方法 |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| EP3302482A4 (en) | 2015-06-05 | 2018-12-19 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US10781205B2 (en) * | 2016-04-20 | 2020-09-22 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising RIPK2 inhibitors |
| WO2018053354A1 (en) | 2016-09-15 | 2018-03-22 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| PL3526202T3 (pl) | 2016-10-11 | 2025-04-28 | Arvinas Operations, Inc. | Związki i sposoby do ukierunkowanej degradacji receptora androgenowego |
| KR20230127371A (ko) | 2016-11-01 | 2023-08-31 | 아비나스 오퍼레이션스, 인코포레이티드 | 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법 |
| CN114656452B (zh) | 2016-12-01 | 2023-01-17 | 阿尔维纳斯运营股份有限公司 | 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物 |
| CN117510491A (zh) | 2016-12-23 | 2024-02-06 | 阿尔维纳斯运营股份有限公司 | 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法 |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES |
| BR112019012682A2 (pt) | 2016-12-23 | 2019-12-17 | Arvinas Operations Inc | moléculas quiméricas visando a proteólise de egfr e métodos associados de uso |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| JP7266526B6 (ja) | 2017-01-26 | 2024-02-15 | アルビナス・オペレーションズ・インコーポレイテッド | エストロゲン受容体タンパク質分解性の調節因子およびその関連方法 |
| CN115974840A (zh) | 2017-01-31 | 2023-04-18 | 阿尔维纳斯运营股份有限公司 | 人小脑蛋白配体和包含其的双官能化合物 |
| WO2019099926A1 (en) | 2017-11-17 | 2019-05-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| CN107987083A (zh) * | 2017-11-24 | 2018-05-04 | 江苏亚盛医药开发有限公司 | 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物 |
| US11220515B2 (en) | 2018-01-26 | 2022-01-11 | Yale University | Imide-based modulators of proteolysis and associated methods of use |
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| JP7515175B2 (ja) | 2018-07-31 | 2024-07-12 | ファイメクス株式会社 | 複素環化合物 |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| WO2020043122A1 (zh) * | 2018-08-28 | 2020-03-05 | 南京明德新药研发有限公司 | 作为rip2激酶抑制剂的喹唑啉类衍生物 |
| US11547759B2 (en) | 2019-01-30 | 2023-01-10 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| US11098025B2 (en) | 2019-01-30 | 2021-08-24 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| EP3941607A1 (en) | 2019-03-21 | 2022-01-26 | Codiak BioSciences, Inc. | Process for preparing extracellular vesicles |
| SG11202109587TA (en) | 2019-03-21 | 2021-10-28 | Codiak Biosciences Inc | Extracellular vesicle conjugates and uses thereof |
| EP3999182A1 (en) | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| JP2021024787A (ja) | 2019-07-31 | 2021-02-22 | ファイメクス株式会社 | 複素環化合物 |
| WO2021020585A1 (ja) | 2019-07-31 | 2021-02-04 | ファイメクス株式会社 | 複素環化合物 |
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| CN115397821B (zh) | 2019-10-17 | 2024-09-03 | 阿尔维纳斯运营股份有限公司 | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 |
| MX2022007678A (es) | 2019-12-19 | 2022-09-19 | Arvinas Operations Inc | Compuestos y metodos para la degradacion dirigida del receptor de androgenos. |
| MX2022014071A (es) | 2020-05-09 | 2023-01-30 | Arvinas Operations Inc | Metodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificacion que comprenden el mismo. |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| US12180193B2 (en) | 2020-08-28 | 2024-12-31 | Arvinas Operations, Inc. | Accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| US12162859B2 (en) | 2020-09-14 | 2024-12-10 | Arvinas Operations, Inc. | Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor |
| US20240025863A1 (en) * | 2020-09-16 | 2024-01-25 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022066928A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| WO2022197862A1 (en) * | 2021-03-17 | 2022-09-22 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| AU2022259683A1 (en) | 2021-04-16 | 2023-10-19 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
| US11981672B2 (en) | 2021-09-13 | 2024-05-14 | Montelino Therapeutics Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| US12419962B2 (en) | 2022-03-16 | 2025-09-23 | Biotheryx, Inc. | Quinazolines, pharmaceutical compositions, and therapeutic applications |
| CA3246569A1 (en) | 2022-03-24 | 2023-09-28 | Glaxosmithkline Ip Dev Ltd | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES USED AS DEGRONS IN PROTACS |
| TW202432544A (zh) | 2022-09-07 | 2024-08-16 | 美商亞文納營運公司 | 快速加速纖維肉瘤降解化合物及相關使用方法 |
| CN115869308B (zh) * | 2022-12-30 | 2024-03-26 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种小分子化合物在制备抗结直肠癌药物中的应用 |
| AU2024212035A1 (en) | 2023-01-26 | 2025-08-14 | Arvinas Operations, Inc. | Cereblon-based kras degrading protacs ans uses related thereto |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| WO2025092821A1 (zh) * | 2023-11-01 | 2025-05-08 | 成都赜灵生物医药科技有限公司 | 喹唑啉衍生物类ripk2抑制剂及其用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4541882B2 (ja) * | 2002-07-02 | 2010-09-08 | ノバルティス アーゲー | Ｓｍａｃタンパク質のアポトーシスタンパク質阻害物質（ｉａｐ）との結合に対するペプチド阻害剤 |
| BRPI0513310A (pt) * | 2004-07-12 | 2008-05-06 | Idun Pharmaceuticals Inc | análogos de tetrapeptìdeo |
| EA017797B1 (ru) | 2007-04-13 | 2013-03-29 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Бициклические диазомиметики smac, способы их получения, их применения, содержащие их фармацевтические композиции и набор, содержащий указанные композиции |
| CA2683392A1 (en) | 2007-04-30 | 2008-11-06 | Genentech, Inc. | Inhibitors of iap |
| WO2009136290A1 (en) * | 2008-05-05 | 2009-11-12 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
| ES2643233T3 (es) | 2009-10-23 | 2017-11-21 | The Regents Of The University Of Michigan | Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos |
| EP2566477B1 (en) * | 2010-05-07 | 2015-09-02 | GlaxoSmithKline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
| UY33549A (es) | 2010-08-10 | 2012-01-31 | Glaxo Group Ltd | Quinolil aminas como agentes inhibidores de las quinasas |
| CA2829131C (en) * | 2011-03-04 | 2018-11-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Amino-quinolines as kinase inhibitors |
| TWI547494B (zh) * | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| KR102438072B1 (ko) * | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| CN104718209A (zh) | 2012-08-23 | 2015-06-17 | 密执安大学评议会 | Iap蛋白的二价抑制剂和使用其的治疗方法 |
| AR092529A1 (es) * | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| TW201425307A (zh) * | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| WO2014047024A1 (en) | 2012-09-18 | 2014-03-27 | Bristol-Myers Squibb Company | Iap antagonists |
| EP2903998B1 (en) | 2012-10-02 | 2017-03-15 | Bristol-Myers Squibb Company | Iap antagonists |
| CN104854100B (zh) | 2012-12-11 | 2017-05-24 | 霍夫曼-拉罗奇有限公司 | 二聚化合物 |
| RU2662810C2 (ru) | 2013-02-21 | 2018-07-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Хиназолины в качестве ингибиторов киназы |
| AU2015247817C1 (en) | 2014-04-14 | 2022-02-10 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| AU2015261812B2 (en) | 2014-05-23 | 2019-11-21 | F. Hoffmann-La Roche Ag | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors |
| EP3189054B1 (en) | 2014-09-05 | 2019-07-24 | Merck Patent GmbH | (1-fluoro-cyclohex-1-yl)-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| TW201642860A (zh) | 2015-04-22 | 2016-12-16 | 塞爾基因定量細胞研究公司 | 布羅莫結構域抑制劑 |
| DK3286181T3 (da) | 2015-04-22 | 2021-04-06 | Rigel Pharmaceuticals Inc | Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne |
| GB201506871D0 (en) * | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US10781205B2 (en) * | 2016-04-20 | 2020-09-22 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising RIPK2 inhibitors |
-
2015
- 2015-04-22 GB GBGB1506872.9A patent/GB201506872D0/en not_active Ceased
-
2016
- 2016-04-20 AU AU2016252404A patent/AU2016252404B2/en not_active Ceased
- 2016-04-20 JP JP2017555322A patent/JP2018513867A/ja not_active Ceased
- 2016-04-20 EA EA201792047A patent/EA033343B1/ru not_active IP Right Cessation
- 2016-04-20 CN CN201680036813.3A patent/CN107709305B/zh not_active Expired - Fee Related
- 2016-04-20 ES ES16783708T patent/ES2841548T3/es active Active
- 2016-04-20 WO PCT/US2016/028332 patent/WO2016172134A2/en not_active Ceased
- 2016-04-20 KR KR1020177033407A patent/KR20170139096A/ko not_active Withdrawn
- 2016-04-20 CA CA2983414A patent/CA2983414A1/en not_active Abandoned
- 2016-04-20 HK HK18102883.6A patent/HK1243410A1/zh unknown
- 2016-04-20 EP EP16783708.7A patent/EP3286169B1/en active Active
- 2016-04-20 BR BR112017022604-9A patent/BR112017022604A2/pt not_active Application Discontinuation
- 2016-04-20 CR CR20170478A patent/CR20170478A/es unknown
- 2016-04-20 SG SG11201708311UA patent/SG11201708311UA/en unknown
- 2016-04-20 MX MX2017013556A patent/MX375674B/es active IP Right Grant
- 2016-04-20 PE PE2017002302A patent/PE20180044A1/es unknown
- 2016-04-20 US US15/568,025 patent/US10435391B2/en not_active Expired - Fee Related
-
2017
- 2017-10-16 IL IL255067A patent/IL255067A0/en unknown
- 2017-10-18 CL CL2017002650A patent/CL2017002650A1/es unknown
- 2017-10-20 PH PH12017501921A patent/PH12017501921A1/en unknown
- 2017-11-21 CO CONC2017/0011851A patent/CO2017011851A2/es unknown
-
2019
- 2019-08-22 US US16/547,734 patent/US20190382381A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3286169A2 (en) | 2018-02-28 |
| HK1243410A1 (zh) | 2018-07-13 |
| CO2017011851A2 (es) | 2018-02-09 |
| EP3286169A4 (en) | 2018-11-21 |
| WO2016172134A2 (en) | 2016-10-27 |
| CL2017002650A1 (es) | 2018-03-16 |
| EA033343B1 (ru) | 2019-09-30 |
| AU2016252404A1 (en) | 2017-12-07 |
| CA2983414A1 (en) | 2016-10-27 |
| EP3286169B1 (en) | 2020-10-07 |
| SG11201708311UA (en) | 2017-11-29 |
| GB201506872D0 (en) | 2015-06-03 |
| PH12017501921A1 (en) | 2018-03-19 |
| US20190382381A1 (en) | 2019-12-19 |
| CN107709305B (zh) | 2020-09-29 |
| US20180134688A1 (en) | 2018-05-17 |
| MX2017013556A (es) | 2018-08-01 |
| JP2018513867A (ja) | 2018-05-31 |
| IL255067A0 (en) | 2017-12-31 |
| US10435391B2 (en) | 2019-10-08 |
| CR20170478A (es) | 2018-01-22 |
| ES2841548T3 (es) | 2021-07-08 |
| CN107709305A (zh) | 2018-02-16 |
| AU2016252404B2 (en) | 2018-07-26 |
| EA201792047A1 (ru) | 2018-04-30 |
| WO2016172134A3 (en) | 2016-12-01 |
| KR20170139096A (ko) | 2017-12-18 |
| BR112017022604A2 (pt) | 2018-07-17 |
| MX375674B (es) | 2025-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20180044A1 (es) | Compuestos novedosos | |
| CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| MX2023007581A (es) | Analogos de rapamicina unidos a c26 como inhibidores de mtor. | |
| AR072063A1 (es) | Mimeticos de glucocorticoides metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos | |
| CU24643B1 (es) | Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47 | |
| AR086829A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| MX2015012815A (es) | Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina 2,3-disustituidos y su uso como inhibidores de bromodominio. | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| PE20180462A1 (es) | Moduladores cot y metodos de uso de los mismos | |
| AR101179A1 (es) | Combinaciones anti-pd-l1 para tratar tumores | |
| PE20160875A1 (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| AR103265A1 (es) | Compuestos de azolina sustituidos con un sistema de anillos condensado | |
| ECSP088926A (es) | Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| PE20220567A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| PE20180121A1 (es) | Imidazopirazinonas como inhibidores de pde1 | |
| PE20160934A1 (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolisis | |
| AR071652A1 (es) | Derivados 2- fenil-piridina substituidos | |
| MX2017015739A (es) | Moduladores de ror gamma (ror?). |